What are the obligations of pharmaceutical companies in a global health emergency?

[...]any satisfactory approach should include mechanisms for assurance that all parties are honouring their obligations. Additionally, market-based arrangements, with patents, marketing exclusivity, and confidentiality clauses, give pharmaceutical companies the freedom to choose what treatments to r...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) 2021-09, Vol.398 (10304), p.1015-1020
Hauptverfasser:	Emanuel, Ezekiel J, Buchanan, Allen, Chan, Shuk Ying, Fabre, Cécile, Halliday, Daniel, Heath, Joseph, Herzog, Lisa, Leland, R J, McCoy, Matthew S, Norheim, Ole F, Saenz, Carla, Schaefer, G Owen, Tan, Kok-Chor, Wellman, Christopher Heath, Wolff, Jonathan, Persad, Govind
Format:	Artikel
Sprache:	eng
Schlagworte:	Accountability Agreements Bilateral agreements Compensation Coronaviruses Costs and Cost Analysis - economics COVID-19 vaccines Developing Countries Drug dosages Drug Industry - ethics Drug Industry - organization & administration Ethics Global Health High income Humans Infectious diseases Intellectual property Knowledge Low income groups Manufacturing Pandemics Pharmaceutical industry Pharmaceuticals Profits Public health Social Responsibility Sustainability Vaccines Viewpoint Wage & price controls
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!